Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2

Interdisciplinary Toxicology

Volumn 1, Issue 2, 2008, Pages 160-168

  Aimová, Dagmar ^a   Poljaková, Jitka ^a   Kotrbová, Věra ^a   Moserová, Michaela ^a   Stiborová, Marie ^a   Frei, Eva ^b   Arlt, Volker M ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

benzo(a)pyrene; cytochromes P450; ellipticine; HRN mice; induction; NADPH:cytochrome P450 reductase

Indexed keywords

EID: 84863130303     PISSN: 13376853     EISSN: 13379569     Source Type: Journal    
DOI: 10.2478/v10102-010-0033-z     Document Type: Article

References (31)

1. Aimová D, Svobodová L, Kotrbová V, Mrázová B, Hodek P, Hudecek J, Václavíková R, Frei E, Stiborová M (2007) The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos 35: 1926-34.
2. Arlt VM, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Stiborova M (2006) Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett 234: 220-31.
3. Arlt VM, Hewer A, Sorg BL, Schmeiser HH, Phillips DH, Stiborova M (2004) 3-Aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2. Chem Res Toxicol 17: 1092-101.
4. Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH, Phillips DH (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H: quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65: 2644-52.
5. Arlt VM, Stiborová M, Henderson CJ, Thiemann M, Frei E, Aimová D, Singh R, Gamboa da Costa, Schmitz OJ, Farmer PB, Wolf CR, Phillips DH (2008) Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29: 656-65.
6. Arlt VM, Stiborova M, Hewer A, Schmeiser HH, Phillips DH (2003) Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH: cytochrome P450 reductase. Cancer Res 63: 2752-61.
7. Baird WM, Hooven LA, Mahadevan B (2005) Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ Mol Mutagen 45: 106-14.
8. Bořek-Dohalska L, Frei E, Stiborová M (2004) DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69: 603-615.
9. Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64: 289-95.
10. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, Wolf CR (2003) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278: 13480-6.
11. Henderson CJ, Pass GJ, Wolf CR (2006) The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicology letters 162: 111-7.
12. IARC Monogr Eval Carcinog Risk Chem Hum (1983) Polynuclear Aromatic Compounds 32, 211.
13. Kotrbová V, Aimová D, Březinová A, Janouchová K, Poljaková J, Hodek P, Frei E, Stiborová M (2006) Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. Neuro Endocrinol Lett 27(Suppl. 2): 18-20.
14. Kouri RE, Salerno RA, Whitmire CE (1973) Relationships between aryl hydrocarbon hydroxylase inducibility and sensitivity to chemically induced subcutaneous sarcomas in various strains of mice. J Natl Cancer Inst 50: 363-8.
15. Phillips DH (1999) Polycyclic aromatic hydrocarbons in the diet. Mutat Res 443: 139-47.
16. Phillips DH (2002) Smoking? related DNA and protein adducts in human tissues Carcinogenesis 23: 1979-2004.
17. Poljaková J, Dračínský M, Frei E, Hudeček J Stiborová, M (2006) The effect of pH? on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect. Czech. Chem. Commun. 71: 1169-1185.
18. Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hrabĕta J, Stiborová M (2007) DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett 252: 270-9.
19. Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudecek J, Phillips DH, Frei E.(2008) Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH: cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 226: 318-27.
20. Stiborová M, Bieler CA, Wiessler M, Frei E (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62: 675-84.
21. Stiborová M, Bořek-Dohalska L, Aimová D, Kotrbová V, Kukačková K, Janouchová K, Rupertová M, Ryšlavá H, Hudeček J, Frei E (2006a) Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - Similarity between human and rat systems. Gen Physiol Biophys 25: 245-261.
22. Stiborová M, Breuer A, Aimová D, Stiborova-Rupertova M, Wiessler M, Frei E (2003a) DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer 107: 885-890.
23. Stiborová M, Martínek V, Rýdlová H, Koblas T, Hodek P (2005) Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett 220: 145-154.
24. Stiborová M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T, Frei E (2007a) Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13 hydroxyellipticine. Int J Cancer 120: 243-251.
25. Stiborová M, Rupertová M, Aimová D, Ryšlavá H, Frei E (2007b) Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 236: 50-60.
26. Stiborová M, Rupertová M, Schmeiser HH, Frei E (2006b) Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap 150: 13-23.
27. Stiborová M, Sejbal J, Bořek-Dohalska L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M, Frei E (2004) The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 64: 8374-8380.
28. Stiborová M, Stiborova-Rupertova M, Bořek-Dohalska L, Wiessler M, Frei E (2003b) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16: 38-47.
29. Svobodová M šístková J, Dračínská H, Hudeček J, Hodek P, Schmeiser HH, Arlt VM, Frei E, Stiborová M (2007) Reductive activation of environmental pollutants 3-nitrobenzanthrone and 2-nitrobenzanthrone. Che. Listy 100: s277-s279.
30. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, Nebert DW (2004) Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 65: 1225-37.
31. Uno S, Dalton TP, Dragin N, Curran CP, Derkenne S, Miller ML, Shertzer HG, Gonzalez FJ, Nebert DW (2006) Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 69: 1103-14.